Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E17.74 EPS (ttm)9.45 Insider Own0.20% Shs Outstand753.00M Perf Week3.19%
Market Cap126.26B Forward P/E13.69 EPS next Y12.24 Insider Trans-3.42% Shs Float750.35M Perf Month14.49%
Income7.22B PEG2.09 EPS next Q2.74 Inst Own81.60% Short Float1.04% Perf Quarter3.64%
Sales22.16B P/S5.70 EPS this Y35.20% Inst Trans0.34% Short Ratio2.75 Perf Half Y10.51%
Book/sh38.09 P/B4.40 EPS next Y9.59% ROA10.00% Target Price184.12 Perf Year3.66%
Cash/sh46.14 P/C3.63 EPS next 5Y8.48% ROE25.70% 52W Range127.70 - 177.64 Perf YTD4.69%
Dividend4.00 P/FCF20.12 EPS past 5Y13.60% ROI12.50% 52W High-5.61% Beta0.81
Dividend %2.39% Quick Ratio4.70 Sales past 5Y7.60% Gross Margin81.00% 52W Low31.30% ATR2.62
Employees17900 Current Ratio5.00 Sales Q/Q9.80% Oper. Margin39.90% RSI (14)72.74 Volatility1.33% 1.58%
OptionableYes Debt/Eq1.20 EPS Q/Q18.50% Profit Margin32.60% Rel Volume1.02 Prev Close167.67
ShortableYes LT Debt/Eq1.12 EarningsJul 27 AMC Payout35.30% Avg Volume2.84M Price167.67
Recom2.40 SMA204.98% SMA507.56% SMA2009.26% Volume0 Change0.00%
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Jul-27-16 07:55AM  Amgen Still Has Many Ways to Win
07:50AM  Major Biotechs See Increased Short Interest Bets at 24/7 Wall St.
07:07AM  Q2 2016 Amgen Inc Earnings Release - After Market Close
Jul-26-16 06:37PM  Fed may edge closer to rate hike at CNBC
05:39PM  Third Point's 1st-half returns boosted by energy credit investments Reuters
04:01PM  Amgen Inc: What to Watch in Q2 Earnings at Motley Fool
10:36AM  5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
10:11AM  AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
09:07AM  One Biotech Plays Red Light, Green Light With the FDA at Motley Fool
Jul-25-16 07:03PM  Cramer: These stocks are about to fall at CNBC
04:59PM  What Are Analysts Recommendations for Biogen in 2016?
04:54PM  Alder Biopharma Migraine Drug Holds Up After 6 Months
03:49PM  Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)
01:05PM  3 Top Biotech Stocks to Buy Now at Motley Fool
12:37PM  Amgen (AMGN) Stock Down Ahead of Q2 Earnings Report
09:30AM  Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
09:10AM  Great Stocks With Rising Dividends
09:05AM  How Kanuma Addition to Alexions Portfolio Impacts Its Earnings
08:49AM  Glaxo (GSK) Q2 Earnings: Can the Stock Pull a Surprise?
07:36AM  Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain?
Jul-24-16 10:12AM  10 Must-See Earnings for the Coming Week at 24/7 Wall St.
Jul-23-16 08:49AM  Great Stocks With Rising Dividends at Kiplinger
Jul-22-16 06:58PM  Fourth Straight Week Of Gains; Buckle Up For Earnings
06:04PM  Pharma Industry Outlook: Fundamentals Remain Strong
04:30PM  Amgen Announces Webcast Of 2016 Second Quarter Financial Results PR Newswire
04:00PM  Amgen Announces 2016 Third Quarter Dividend PR Newswire
01:51PM  Amgen 2Q Earnings: Here's What To Expect
01:00AM  Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA PR Newswire
Jul-21-16 03:54PM  Will Alexion Pharmaceuticals 2Q16 Earnings Surprise?
12:07PM  Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin at The Wall Street Journal
11:25AM  Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results
10:16AM  Amgen, Allergan biosimilar found as effective as Roche cancer drug Reuters
10:02AM  Biogen: CEO Departing; Is This Drug Maker In Play? at
09:30AM  The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
09:00AM  Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer PR Newswire
Jul-20-16 08:29PM  Amgen Announces Settlement Of Securities Litigation PR Newswire
03:42PM  Better Buy: Gilead Sciences Inc. vs. Amgen Inc. at Motley Fool
03:36PM  Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
12:05PM  Amgens Kyprolis with Ligand Pharmaceuticalss Captisol Technology
09:47AM  Biotech: As Cheap as They Come at
09:44AM  These new drugs might never get a chance to save the U.S. $250 billion at MarketWatch
Jul-19-16 01:07PM  Novartis Set To Become Biosimilar Pioneer By 2020 at Forbes
08:42AM  U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta Reuters
Jul-18-16 06:49PM  Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
12:07PM  Biogen: Key Analyst Recommendations in 2016
08:02AM  3 Drug Stocks to Report Earnings on Jul 19: JNJ, NVS, NEOG
12:30AM  [$$] Biotech dives into Sardinia gene pool for secret of long life at Financial Times
Jul-17-16 03:03PM  3 Biotech Stocks for Conservative Investors at Motley Fool
Jul-16-16 09:03AM  4 Rock-Solid, Cheap Biotech Stocks at Motley Fool
Jul-15-16 05:29PM  Two of the Worlds Best-Selling Drugs Are Headed for a Lot More Competition at Fortune
03:51PM  Will Biogen Report Strong 2Q16 Revenue Growth?
09:30AM  Valeant psoriasis drug's suicide risk hard to assess -FDA Staff Reuters
Jul-14-16 04:42PM  Drug Companies Really Dont Care About the Price Hike Backlash at Fortune
03:55PM  Better Days Ahead for Biotech at
12:06PM  Novartis' Enbrel Biosimilar Gets FDA Panel Recommendation
11:49AM  Can Strong JP Morgan Earnings Distract from Bearish UK Rate Decision?
11:45AM  FDA committee supports approval of Sandoz biosimilar for Amgen's blockbuster Enbrel at MarketWatch
10:16AM  Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan
09:30AM  The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx
04:48AM  [$$] Biosimilars set topple two of the world's biggest drug franchises at Financial Times
Jul-13-16 09:00PM  Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan PR Newswire
04:31PM  Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June at Motley Fool
03:22PM  Merck to Axe Jobs As Part of New Research Focus at Fortune
03:17PM  Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
03:03PM  U.S. FDA panel supports Novartis version of Amgen arthritis drug Reuters
12:39PM  Why Amgens positive biosimilar news isnt as good as it seems at MarketWatch
11:29AM  [$$] Three Biotech Picks With Pipeline Upside at
08:10AM  Short Sellers Become More Selective on Major Biotechs at 24/7 Wall St.
07:27AM  [$$] A Threat to Biotechs, but a Slow-Motion One at The Wall Street Journal
Jul-12-16 09:55PM  Merck to open new Cambridge facility for microbiome research this year at
09:06PM  Regenerons Robust Pipeline
05:49PM  FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
05:39PM  Lower-cost biotech drug gets thumbs up from FDA panel
05:30PM  Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere at
04:59PM  Amgen Moves Closer to Selling Competitor for AbbVies Humira at Bloomberg
04:32PM  U.S. FDA panel backs Amgen copy of AbbVie arthritis drug Humira Reuters
01:49PM  [$$] A Threat to Biotechs, but a Slow-Motion One at The Wall Street Journal
01:08PM  Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)s Cancer Blockbuster at Insider Monkey
12:17PM  Biotech: Buy the Stock Get the Pipeline for FreeAgain! at
10:20AM  Amgen's Repatha Gains FDA Approval for New Dosing Option
10:10AM  Biotechs With Drug Pipelines Closest to Zero Valuation at 24/7 Wall St.
09:27AM  Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR) at Motley Fool
09:08AM  Whats Driving Regenerons Premium Valuation?
07:30AM  Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab PR Newswire
Jul-11-16 06:00PM  [$$] Lawrence Bock, Pioneering Biotech Investor, Dies at 56 at The Wall Street Journal
11:37AM  UPDATE 2-Novartis copy of Amgen arthritis drug highly similar -FDA staff Reuters
10:27AM  Amgen Gets FDA Approval For PCSK9 Inhibitor
10:05AM  The Word on the Street: How Analysts See BioMarin Now
09:07AM  Is It Slower Growth for Regenerons Eylea in 2016 and 2017?
09:00AM  FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor PR Newswire
08:13AM  Novartis copy of Amgen arthritis drug highly similar -FDA staff Reuters
08:04AM  Amgen Humira Biosimilar Briefing Documents Look Good
05:11AM  Four high-quality biotech companies trading like risky startups at MarketWatch
01:04AM  How Much Upside Potential Does Alexion Have?
Jul-09-16 12:01AM  [$$] Tracing the Roots of Economic Theory Back to France at
Jul-08-16 04:19PM  Amgen's Biosimilar Humira Gets FDA Support Ahead Of Panel
12:40PM  Amgen drug appears 'highly similar' to Humira -FDA staff Reuters
08:12AM  FDA staff say Amgen biosimilar "highly similar" to Abbvie's Humira
06:50AM  Feuerstein: Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks
Jul-07-16 06:11PM  [$$] Carmot Therapeutics Forms Drug-Discovery Deal With Genentech at The Wall Street Journal
Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM